Estrogen Replacement Therapy Should NOT Be Used for Cardiovascular Protection in Postmenopausal Women
Do not prescribe estrogen replacement therapy (ERT) or combined estrogen-progestin therapy (HRT) for the purpose of preventing heart disease in postmenopausal women, regardless of whether they have existing coronary disease. The highest quality evidence from randomized controlled trials demonstrates that hormone therapy increases cardiovascular risk rather than providing protection 1.
The Evidence Against Cardiovascular Use
For Women WITHOUT Existing Heart Disease (Primary Prevention)
The U.S. Preventive Services Task Force issues a Grade D recommendation (recommends against) using hormone therapy for chronic disease prevention 1, 2. This applies to both:
- Combined estrogen-progestin therapy: Grade D recommendation against routine use
- Estrogen alone (in women with hysterectomy): Grade D recommendation against use
The Women's Health Initiative (WHI) trial—the definitive randomized controlled study—showed that for every 10,000 women taking estrogen plus progestin for one year 2:
- 7 additional coronary heart disease events
- 8 additional strokes
- 8 additional pulmonary emboli
- 8 additional invasive breast cancers
These harms outweigh the benefits (6 fewer colorectal cancers and 5 fewer hip fractures).
For Women WITH Existing Heart Disease (Secondary Prevention)
The Heart and Estrogen-Progestin Replacement Study (HERS) definitively showed no reduction in overall risk for nonfatal MI or coronary death in postmenopausal women with established coronary disease 3. More concerning, there was a statistically significant increase in coronary events during the first year of hormone therapy, with a relative risk of 1.80 (95% CI, 1.08–2.99) 4.
The 2020 Endocrine Society guidelines explicitly state: "hormone therapy increases the risk of cardiovascular disease, specifically venous thromboembolism and stroke" and "we do not recommend the use of hormone therapy to treat dyslipidemia" 4.
Why the Contradiction with Older Observational Data?
Earlier observational studies from the 1990s suggested cardiovascular benefits, but these were fundamentally flawed by "healthy-user" bias—women who chose to take hormones were already healthier and more health-conscious 5, 6. The randomized controlled trials eliminated this bias and revealed the true harmful effects.
The "Timing Hypothesis" Does Not Change Clinical Practice
Some have proposed that starting hormones immediately at menopause (rather than years later) might provide benefit. However, this remains unproven in randomized trials 4, 7. The 2020 Endocrine Society guidelines note that hormone therapy "increases CVD risk, especially if started late (>age 60 years or >10 years postmenopause)" but still conclude the evidence shows harm, not benefit 4.
While younger women closer to menopause may have lower absolute risk, this does not translate to a recommendation for cardiovascular protection 7, 8.
What About Lipid Effects?
Yes, estrogen improves lipid profiles—it decreases LDL cholesterol by up to 20% and increases HDL cholesterol by up to 15% 4. However, favorable lipid changes do not translate to cardiovascular benefit. The HERS trial showed an 11% lower LDL and 10% higher HDL in the hormone group, yet there was still no reduction in coronary events and an early increase in risk 3.
This demonstrates that lipid effects account for only about 25% of cardiovascular outcomes, and other mechanisms (increased thrombosis, inflammation) override any lipid benefits 6.
Critical Clinical Pitfalls to Avoid
- Do not prescribe hormone therapy to prevent heart disease, even in women with multiple cardiac risk factors
- Do not continue hormone therapy in women who develop cardiovascular disease while on treatment
- Do not assume "natural" or bioidentical hormones are safer—the evidence applies to all estrogen formulations 4, 2
- Do not use transdermal estrogen thinking it avoids cardiovascular risk—while it may have less effect on lipids, cardiovascular harm persists
What TO Do Instead for Cardiovascular Protection
For postmenopausal women requiring cardiovascular risk reduction:
- Prescribe statins if indicated by cardiovascular risk factors 4
- Recommend lifestyle modifications (diet, exercise, smoking cessation)
- Control hypertension and diabetes
- Consider aspirin for appropriate candidates
If a woman is already on hormone therapy for other cardiovascular risk factors, the 2020 guidelines recommend: "we recommend statin therapy to reduce CV risk" 4.
The Only Acceptable Use of Hormone Therapy
Hormone therapy remains appropriate only for managing menopausal symptoms (hot flashes, night sweats, vaginal dryness) in women without contraindications 2, 7. In this context:
- Use the lowest effective dose
- For the shortest duration necessary
- Reassess need regularly
- Accept that cardiovascular risk exists even for symptom management
The cardiovascular system is not an indication for hormone therapy—it is a source of harm that must be weighed against symptom relief benefits.